United States

Report: 7,800 Florida clinical trials conducted since 1999

Monday, September 16, 2013 03:07 PM

Working in collaboration with Florida clinicians and research institutions, America’s biopharmaceutical research companies have conducted more than 7,800 clinical trials of new medicines in Florida over the last 14 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

More... »

ClinicalRM awarded NIH contract

Monday, September 16, 2013 08:52 AM

CRO Clinical Research Management was awarded a contract by the Department of Health and Human Services, NIH, Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). The intent of the award is to provide a broad spectrum of services for the design and conduct of phase I-IV clinical trials and clinical studies focused on the screening, diagnosis, treatment, prevention and control of sexually transmitted infections within the Sexually Transmitted Infections Clinical Trials Group (STI CTG) Program.

More... »

Celtaxsys restructures, enhances operational focus

Monday, September 16, 2013 08:43 AM

Celtaxsys, an Atlanta-based pharmaceutical discovery and development company, has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis.

More... »

NIH scientists pursue new therapies to improve rare disease drug development

Monday, September 16, 2013 08:00 AM

Four new preclinical drug development projects at the NIH will target a form of blindness and diseases characterized by cardiac problems. The projects were selected for their potential to treat specific rare diseases and to help scientists uncover new information that can be shared with other researchers.

More... »

Theorem, Charles River collaborate

Friday, September 13, 2013 01:17 PM

CROs Theorem Clinical Research and Charles River Laboratories are collaborating to provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration. The alliance provides nonclinical testing programs in bioanalysis, immunogenicity and immunology to support clinical trials.

More... »

Bruker acquires Prairie Technologies

Friday, September 13, 2013 01:15 PM

Bruker, a provider of scientific instruments and solutions for molecular and materials research, has acquired Prairie Technologies, a provider of life science fluorescence microscopy products.

More... »

Genia, Columbia, Harvard awarded DNA sequencing technology grant

Friday, September 13, 2013 01:10 PM

Genia Technologies has announced, as part of a research consortium with Columbia University and Harvard Medical School, it has received a Revolutionary Genome Sequencing Technologies—The $1,000 Genome grant from the National Human Genome Research Institute (NHGRI) of the NIH.  The grant, $5.25 million for three years, will be used in collaboration with investigators at Columbia and Harvard to further develop Genia's nanopore-based DNA sequencing platform that allows for single molecule, electrical, real-time analysis.  

More... »

Michael J. Fox Foundation unites industry groups for research tool development

Friday, September 13, 2013 01:07 PM

The Michael J. Fox Foundation for Parkinson's research (MJFF) has launched the Parkinson's Disease Research Tools Consortium. MJFF and seven industry partners have organized to grow the Foundation's ongoing efforts to better understand existing tools—such as preclinical models, antibodies and cell lines—and their use in laboratory experiments, as well as to develop new tools to address unmet challenges.

More... »

Rigel refocuses resources, cuts 30 jobs

Tuesday, September 10, 2013 11:01 AM

Rigel Pharmaceuticals plans to focus resources on the completion of three lead clinical programs. These efforts include a phase III clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura (ITP), pending discussions with regulatory agencies. Rigel believes that a phase III clinical program would encompass approximately 150 patients and can be completed in 2015.

More... »

Nuclea Biotechnologies acquires Oncogene Science, extends Wilex cooperation

Monday, September 9, 2013 12:05 PM

Pittsfield, Mass.-based Nuclea Biotechnologies has acquired all shares of Cambridge, Mass.-based Wilex (Oncogene Science), a wholly owned U.S. subsidiary of Wilex.

More... »